Dorsey Wright & Associates purchased a new stake in shares of AstraZeneca plc (NYSE:AZN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 146,134 shares of the company’s stock, valued at approximately $5,782,000.
Other institutional investors and hedge funds have also recently made changes to their positions in the company. NEXT Financial Group Inc acquired a new position in shares of AstraZeneca during the third quarter valued at $169,000. Bessemer Group Inc. boosted its holdings in shares of AstraZeneca by 64.3% during the second quarter. Bessemer Group Inc. now owns 4,651 shares of the company’s stock valued at $163,000 after acquiring an additional 1,820 shares during the period. FNY Investment Advisers LLC acquired a new position in shares of AstraZeneca during the second quarter valued at $175,000. Tiverton Asset Management LLC acquired a new position in shares of AstraZeneca during the second quarter valued at $178,000. Finally, Gilman Hill Asset Management LLC acquired a new position in shares of AstraZeneca during the second quarter valued at $205,000. 15.97% of the stock is owned by institutional investors.
Several brokerages have recently issued reports on AZN. ValuEngine raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Thursday, September 27th. Jefferies Financial Group downgraded shares of AstraZeneca from a “buy” rating to a “hold” rating in a report on Thursday, August 16th. Zacks Investment Research raised shares of AstraZeneca from a “hold” rating to a “buy” rating and set a $44.00 price objective for the company in a report on Tuesday. Finally, Guggenheim initiated coverage on shares of AstraZeneca in a report on Monday. They issued a “buy” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $39.78.
In related news, major shareholder Plc Astrazeneca acquired 246,666 shares of AstraZeneca stock in a transaction that occurred on Friday, September 28th. The stock was acquired at an average price of $15.00 per share, with a total value of $3,699,990.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
AZN stock traded down $0.49 during trading on Friday, hitting $37.15. The company had a trading volume of 3,709,900 shares, compared to its average volume of 3,962,704. The company has a market capitalization of $100.23 billion, a P/E ratio of 8.68, a PEG ratio of 2.10 and a beta of 0.58. AstraZeneca plc has a fifty-two week low of $31.99 and a fifty-two week high of $40.16. The company has a quick ratio of 0.54, a current ratio of 0.72 and a debt-to-equity ratio of 1.08.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Thursday, July 26th. The company reported $0.69 earnings per share for the quarter, topping the consensus estimate of $0.31 by $0.38. The business had revenue of $5.16 billion during the quarter, compared to the consensus estimate of $5.09 billion. AstraZeneca had a net margin of 11.98% and a return on equity of 29.89%. The company’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.87 earnings per share. Equities analysts anticipate that AstraZeneca plc will post 1.68 EPS for the current year.
AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.
Recommended Story: How analysts view the yield curve
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca plc (NYSE:AZN).
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.